Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization

Sebastian Kuger1, Michael Flentje2, Cholpon S Djuzenova2

  • 1Department of Radiation Oncology, University Hospital of Würzburg, Würzburg, Germany. melanie.gardeur@biomedcentral.com.

Abstract

Insights

Simultaneous inhibition of MAPK/ERK kinase (MEK) and PI3K/mammalian target of rapamycin (mTOR) pathways radiosensitizes cancer cells, but combining MEK and PI3K/mTOR inhibitors does not enhance this effect. The drug combination shows cell line-specific cytostatic effects rather than synergistic radiosensitization.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are crucial in cancer.
  • Simultaneous inhibition of these pathways can synergistically reduce tumor size and prolong survival.
  • Previous studies show that inhibiting these pathways can radiosensitize cancer cells.

Purpose of the Study:

  • To investigate if phenotypic changes after perturbing the MAPK/ERK kinase (MEK) and PI3K/mTOR signaling network depend on the genetic background.
  • To assess the effects of simultaneous MEK and PI3K/mTOR inhibition combined with ionizing radiation (IR) on cancer cells.
  • To determine if combining MEK and PI3K/mTOR inhibitors leads to synergistic radiosensitization.

Main Methods:

  • Glioblastoma and lung carcinoma cells with differing mutational statuses were treated with MEK inhibitor AZD6244 and dual PI3K/mTOR inhibitor NVP-BEZ235.
  • Cell proliferation was measured using an ATP assay.
  • Signaling pathway perturbations, colony formation, apoptosis, autophagy, and cell cycle changes were analyzed over time following drug treatment and/or IR.

Main Results:

  • Both AZD6244 and NVP-BEZ235 reduced tumor cell proliferation dose-dependently, with NVP-BEZ235 being more potent.
  • AZD6244 moderately radiosensitized cancer cells, while NVP-BEZ235 showed stronger radiosensitization; combining them did not enhance this effect.
  • The drug combination induced synergistic G1-phase arrest, apoptosis, and autophagy in a cell line- and drug-specific manner, but not synergistic radiosensitization.

Conclusions:

  • Perturbing MEK and PI3K pathways radiosensitizes tumor cells, and the combination of AZD6244 and NVP-BEZ235 exhibits cytostatic effects.
  • Simultaneous treatment with AZD6244 and NVP-BEZ235 does not result in synergistic radiosensitization.
  • The combination therapy demonstrates cell line-specific effects on cancer cell phenotypes, including cell cycle arrest, apoptosis, and autophagy.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K